Menu Search
Equities

Energenesis Biomedical Co Ltd

6657:TAI

Energenesis Biomedical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (TWD)52.00
  • Today's Change-0.10 / -0.19%
  • Shares traded42.06k
  • 1 Year change-14.05%
  • Beta--
Data delayed at least 20 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in TWDIncome statement in TWDView more

Year on year Energenesis Biomedical Co Ltd had relatively flat revenues (7.35m to 7.16m), though the company grew net income from a loss of 265.66m to a smaller loss of 260.38m. A reduction in the cost of goods sold as a percentage of sales from 29.74% to 26.98% was a component in the net income growth despite flat revenues.
Gross margin73.90%
Net profit margin-2,936.00%
Operating margin-3,174.15%
Return on assets-23.36%
Return on equity-24.40%
Return on investment-24.32%
More ▼

Cash flow in TWDView more

In 2023, Energenesis Biomedical Co Ltd increased its cash reserves by 173.42%, or 156.41m. Cash Flow from Financing totalled 440.42m or 6,152.84% of revenues. In addition the company used 225.05m for operations while cash used for investing totalled 58.96m.
Cash flow per share-2.31
Price/Cash flow per share--
Book value per share9.53
Tangible book value per share9.26
More ▼

Balance sheet in TWDView more

Energenesis Biomedical Co Ltd has little financial risk as the capital structure does not rely on leverage.
Current ratio26.76
Quick ratio26.74
Total debt/total equity0.0114
Total debt/total capital0.0112
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.